Season 4, Episode Special1 - A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance
Currently, screening for hepatocellular carcinoma (HCC) in patients with cirrhosis is recommended to reduce mortality from HCC.
This EASL Studio Special Edition will discuss the newly updated EASL policy statement, Risk-based surveillance for hepatocellular carcinoma among patients with cirrhosis.
Tune in to learn:
- What is risk-based screening ?
- How will this new strategy affect the overall patient journey?
- How can such recommendations be implemented at the European level?
Faculty: Prof. Thomas Berg (Moderator), Prof. Harry de Koning (Faculty), Mr. Pietro Fiocchi (Faculty), Prof. Peter Jepsen (Faculty), Mrs. José Willemse (Patient Perspective)
ℹ The episode will be broadcasted live on this page.
